The evolutionarily conserved Wnt signaling pathway regulates physiological hematopoiesis, a process of formation of blood cells and has been shown to play crucial role in the development of both myeloid and lymphoid malignancies. The Wnt signaling pathway can be broadly divided into canonical and non-canonical pathways. In the present study, we investigated the pathobiology of leukemia by studying the expression profile of Wnt proteins, receptors, key signaling intermediates and endogenous Wnt antagonist involved in canonical and non-canonical pathways in the bone marrow (BM) hematopoietic stem/progenitor cell (HSPC) compartment of experimental leukemic mice. Cell adhesion molecule N-Cadherin and leukemic BM microenvironment with reference to Wnt were also studied. We used ENU, a potent carcinogen, to induce leukemia in wild type Swiss albino mice and malignant transformation was cofirmed by peripheral blood and BM studies. Flow cytometric expression analysis revealed profound up-regulation of canonical Wnt3a/β-catenin/CyclinD1 signaling axis along with N-Cadherin whereas down-regulation of non-canonical Wnt5a/Ca 2+ /CaMKII signaling axis in the leukemic HSPC compartment. Subsequent use of anti-Wnt3a antibody in the in vitro clonogenicity assay uncovered that anti-Wnt3a antibody preferentially inhibited the growth and number of the primitive leukemic hematopoietic CFU-GEMM and BFU-E colonies. Stromal cells derived from the leukemic BM also exhibited aberrant Wnt3a and Wnt5a protein expression. Taken together, alteration of canonical and non-canonical Wnt signaling pathways in the HSPC compartment along with classical Wnt protein expression pattern in the leukemic stromal microenvironment resulted in progression of leukemia.
Introduction
The Wnt pathway, an evolutionarily conserved developmental signaling pathway, plays an important role during embryogenesis and also regulates crucial aspects of adult hematopoiesis. It is a complex signaling pathway and signaling output depends on the ligand-receptor interaction and cellular context. To date, approximately 19 Wnt proteins and 10 Frizzled (Fzd) receptors have been identified. Signaling activation and Sukalpa Chattopadhyay and Malay Chaklader contributed equally to this work subsequent signal transduction in the cytoplasm relies on Wnt ligand binding with the extracellular domain of Fzd receptor (Lento et al. 2013; Kim et al. 2014; Zhan et al. 2017; Bigas et al. 2013; Luis et al. 2012; Richter et al. 2017) . Wnt signaling can be broadly divided into β-catenin dependent canonical pathway and β-catenin independent non-canonical pathways. Wnt3a is a classical canonical Wnt ligand, which upon binding to Fzd receptor and LRP5/6 co-receptor causes nuclear translocation of β-catenin that promotes the associated target gene expression to regulate cellular function. Unlike canonical, non-canonical Wnt signaling pathway is more diverse and comparatively less characterized. Wnt5a, a classical noncanonical Wnt ligand, upon binding with Fzd receptor releases intracellular Calcium (Ca 2+ ) ion and activates Ca 2+ responsive regulators such as Calcineurin, CaMKII and PKC in order to exert cellular function (Lento et al. 2013; Schreck et al. 2014; Many and Brown 2014; De 2011) . Wnt5a also interacts with ROR2, a member of the ROR family orphan receptor tyrosine kinases, to transduce β-catenin independent signaling via JNK, RhoA etc. and has been shown to inhibit canonical β-catenin pathway (Minami et al. 2010; Yan et al. 2016) .
During neoplastic transformation normal cellular mechanisms are either hyper-activated or suppressed lead to alteration of cell fate. Leukemia -a hematopoietic malignancycharacterized by unconstrained production of hematopoietic precursor cells which don't differentiate into mature blood cells and accumulate as leukemic blasts in the bone marrow microenvironment and eventually release into the peripheral circulation. Increased expression of β-catenin and constitutive activation of the canonical Wnt pathway has been detected in neoplastic cells of both hematopoietic and non-hematopoietic origin (Wang et al. 2010; Ysebaert et al. 2006; Polakis 2012) . On the contrary, the exact role of non-canonical Wnt signaling pathway in normal as well as in malignant condition is elusive. It has been shown that non-canonical Wnt signaling pathway can inhibit canonical Wnt/β-catenin pathway [Topol et al. 2003; Mikels and Nusse 2006; Ishitani et al. 2003 ] and Wnt5a acts as a tumor suppressor in hematological neoplasms (Martín et al. 2010; Ying et al. 2007; Ng et al. 2015; Zhou et al. 2017; Liang et al. 2003) . However, tumor promoting activity of Wnt5a has also been detected in few human malignancies (Bellon et al. 2013; Bakker et al. 2013) . Although both canonical and non-canonical Wnt pathways have been separately studied, the crosstalk between the two has recently gained much attention as a fundamental mechanism controlling many biological processes such as hematopoietic stem cell ageing and function, drug induced differentiation of leukemia cell line, protein expression in the blood-brain barrier cells, regulation of osteogenic differentiation potential of periodontal ligament stem cells, drug resistance in colon cancer cells etc. (Florian et al. 2013; Zang et al. 2014; Pinzón-Daza et al. 2014; Liu et al. 2016; Bordonaro et al. 2011) . In all of the above mentioned conditions different components of both the canonical and non-canonical Wnt pathways are simultaneously fine tuned either by endogeneous or exogeneous forces to control different cell fate.
In the present study, we investigated the pathobiology of leukemia by studying the altered cross-talk between the canonical Wnt/β-catenin, non-canonical Wnt/Ca 2+ and Wnt/ ROR2 signaling pathways in the bone marrow hematopoietic stem/progenitor cell (HSPC) compartment of ENU induced experimental leukemic mice. Outcome of the present study indicates multiple deregulated points of Wnt signaling pathway in leukemia which can be utilized for future therapeutic purposes.
Materials and Methods

Mice and leukemia induction
Inbred Swiss albino mice (Mus Musculus) were maintained in the animal facility at the Calcutta School of Tropical Medicine under pathogen free standard experimental conditions (22 ± 2°C temperature, controlled humidity and 12 h dark-light cycle) and were given standard diet and water ad libitum. For leukemia induction, 5-10 days old litter pups (N = 30) were given a single intraperitoneal ENU Sigma, injection at a dose rate of 80 mg/kg body weight Law et al. 2001; Basak et al. 2010; Chatterjee et al. 2016b ). The control group (N = 30) received 0.9% intraperitoneal saline injection. The animal groups were monitored carefully for the period of 4-7 months for leukemia development. All animal protocols followed were approved by the Institutional Animal Ethical Committee (IAEC).
Peripheral blood hemogram
Blood was collected from the tail vein of control and leukemic mice into heparinised vials~180 days after the ENU administration. The total leukocyte count and differential leukocyte count were performed as per our previously described protocol Pereira and Law 2018) .
Bone marrow (BM) isolation and single cell preparation
Control and leukemic mice were sacrificed~180 days after the ENU administration by cervical dislocation and long bones (femur and tibia) were removed. The BM was flushed out by 24 gauge needle into ice-cold RPMI-1640 (Sigma) with 10% FBS (Lonza). The BM cells were washed thrice, repeat pipetted and passed through 100 μm wire mesh to prepare single cell suspension.
Marrow smear study
Marrow smears were prepared, stained with May-Grunwald Giemsa and examined under the light microscope (Olympus CH20i) for morphological analysis.
Cytochemistry
Myeloperoxidase (MPO): BM smears were incubated in buffer formal acetone and then in 3,3'-Diaminobenzidine (DAB) solution for 15-20 min, counterstained with Hematoxylin and examined under light microscope.
Nonspecific-esterase (NSE): BM smears were incubated in a solution containing pararosaniline-sodium nitrite and α-napthyl acetate for 20 min, counter-stained with Hematoxylin and examined under light microscope.
Immunophenotyping
2X10
6 paraformaldehyde (PFA) fixed control and leukemic BM cells were stained with following antibodies: anti-CD117-FITC (BD Pharmingen), anti-CD22-FITC, antiCD79a-FITC (Biolegend), anti-CD10-FITC (Santa Cruz Biotechnology), anti-CD3-PE (Biolegend). Data acquired by BD-FACS Calibur and analyzed by Cell Quest Pro software. Forward scatter (FSC) vs antigen expression strategy (Weir et al. 2007 ) was used for analysis and antigen expression was considered as positive by comparing with the control.
Flow cytometry
Flow cytometry was performed to analyze expression profile of Wnt signaling components in control and leukemic condition as per our previously described protocol Daw et al. 2016; Chatterjee et al. 2016c; Chattopadhyay et al. 2016b ).
Hematopoietic clonogenicity assay with anti-Wnt3a antibody
Clonogenicity assay was performed in methylcellulose-based semisolid media which consisted of 1.2% methylcellulose (Sigma), 30% FBS, 1% BSA (Sigma), 0.02% β-ME and growth factors [100 ng/ml recombinant mouse (rm) SCF, 50 ng/ml rm IL-3 and 50 ng/ml rm GM-CSF]. RBC lysed control and leukemic BM cells were plated at a concentration of 5X10 5 cells/ml with and without anti-Wnt3a antibody (100 ng/ml) (Santa Cruz Biotechnology) in triplicate and cultured at 37°C in a 5% CO 2 incubator. After 16 days the numbers of hematopoietic colonies (viz, CFU-GEMM, CFU-G, CFU-GM, BFU-E and CFU-E) were scored manually under the inverted microscope.
Fluorescence imaging
N-Cadherin expression was studied by immunofluorescence imaging. BM cells were stained with anti-N-Cadherin primary antibody (Santa Cruz Biotechnology; 1:300 dilution) and Alexa Fluor 488 tagged secondary antibody (1:600 dilution) as per the protocol described previously . Cells were counterstained with DAPI shield (Sigma) and examined by confocal microscope (Leica TCS SP8 Laser Scanning Confocal Microscope).
Long-term BM culture (LT-BMC)
BM cells at a concentration of 2X10 6 cells/ml were plated in six well cell culture plates (Corning) containing 3 ml RPMI-1640, 30% FBS, 1% BSA, 0.02% β-ME and cultured at 37°C in a 5% CO 2 incubator. After 72 h, the non-adherent cells were removed by washing and the media was replenished every 3 days to grow adherent BM stromal cells. The culture plates were monitored at day 7, 10, 15 and 20 for cellular growth pattern assessment and photographed (Chaklader and Law 2015) .
Immunocytochemistry (ICC)
LT-BMC was used to grow BM stromal cells. Stromal cells were stained with anti-Wnt3a and anti-Wnt5a antibody (1:300 dilution) overnight at 4oC according to the protocol of (Chaklader and Law 2015) . Cells were washed and stained the following day for 2 h with HRP tagged secondary antibody (1:600 dilution) (Invitrogen). The reaction product was developed chromogenically by DAB and examined under light microscope after counterstaining with Hematoxylin.
Dot blot assay
Dot blot assay was performed as per the standard protocol to determine the level of Dkk1 in the BM stromal cell culture supernatant. Briefly, the culture supernatant was collected, blotted onto nitrocellulose membrane and further processed conventionally. Next, the membrane was stained with antiDkk1 primary antibody (1:300 dilution; Santa Cruz Biotechnology) followed by HRP tagged secondary antibody (1:600 dilution) and the reaction product was developed using HRP-DAB based chromogenic method.
Statistics
Statistical analysis was performed using unpaired student's ttest and quantitative values were represented as Mean ± SD. In addition, one-way ANOVA followed by Posthoc Tukey tests were used when differences between more than two groups were evaluated. For all comparisons, P ≤ 0.05 was considered as significant difference. Each experiment was repeated thrice.
Results
Neonatal ENU administration leads to development of mixed type leukemia
Neonatal [P5-10] ENU administered mice showed signs of leukemia development within a period of 4-7 months after injection (Fig. 1a) and Kaplan-meier analysis revealed the median survival was 200 days (Fig. 1b) . Therefore, to investigate the pathological features and Wnt signaling, we choose~180 days as the optimum time required for neoplastic transformation. 63.66% mice developed leukemia after ENU induction and rest of the mice died due to acute ENU toxicity (13.13%) and secondary reasons (23.21%) (Fig. 1c) . Peripheral blood count was considered as the initial predictive tool for the confirmation of leukemic onset, which showed a significant leukocytosis (Ctrl 6 ± 1.2X10 3 and Leukemia 35 ± 2.6X10 3 cells/μl) [P < 0.05] (Fig. 1d ) along with massive infiltration of morphologically distinct myeloblasts and lymphoblasts ( Fig. 1e ) (total blast count: 34.29 ± 4.26%). These findings initially indicated mixed type leukemia development. Unlike control (Fig. 1f) examination of the BM compartment showed clear sign of hematopoietic malignancy i.e. huge accumulation of undifferentiated precursor cells and very few numbers of residual differentiated hematopoietic cells (Fig. 1g) . Next, we studied the lineage specific antigens according to the revised WHO guidelines (Vardiman et al. 2009 ). Myeloblasts were identified by MPO and NSE cytochemistry in addition to CD117 expression. Leukemic cells were CD117 positive (Fig. 2b right panel) , strongly MPO (enzyme activity exclusively present in the azurophilic granules of myeloid cells) positive (Fig. 2a  upper right panel) and a few cells showed NSE (membrane bound enzymes exclusively present in the monocytes) positivity (Fig. 2a lower right panel) , altogether confirmed presence of myeloblasts. Blymphoblasts were identified primarily by the expression of CD22, a specific antigen for B-lymphoid cells, in addition to CD79a and CD10 in the leukemic BM (Fig. 2b right panel) . T-lymphoblasts, on the other hand, were identified by the expression of CD3, an antigen unique to T-lymphoid cells (Fig. 2b right  panel) . To sum up, we have observed both myeloblasts and lymphoblasts in the leukemic blood and antigen expression in the BM, which indicated the development of mixed type leukemia in the adult mice after neonatal ENU induction. (Fig. 3a-b) . In vitro clonogenicity assay uncovered that supplementation of antiWnt3a antibody significantly inhibited the growth of primitive hematopoietic colonies such as multipotent CFU-GEMM (Colony-forming unit of granulocyte/erythrocyte/ macrophage/megakaryocyte) and BFU-E (Burst-forming unit of erythroid cells). However, no significant changes were observed in case of comparatively matured colony numbers such as CFU-GM (Colony-forming unit of granulocyte/macrophage), CFU-G (Colony-forming unit of granulocyte) and CFU-E (Colony-forming unit of erythroid cells) after supplementation of anti-Wnt3a antibody ( Fig. 4a-b) . (Fig. 3a-b) .
Expression pattern of cell adhesion molecule N-Cadherin in the leukemic marrow
Differential expression of CAM molecules (Cell adhesion molecule) regulate behaviour and aggressiveness of variety of solid tumors (Chaklader et al. 2013) . Here, we studied N-Cadherin (CD325), a Ca 2+ dependent CAM and a member of cadherin superfamily, expression in the hematopoietic malignancy. Flow cytometric analysis showed huge up-regulation of N-Cadherin expression in the leukemic primitive HSPC compartment when compared to control (MFI: Ctrl 32.25 ± 1.98 and Leukemia 168.05 ± 2.51) [P < 0.0001] (Fig. 4c) . Confocal microscopy also confirmed higher N-Cadherin expression in the leukemic cells (Fig. 4d lower panel) . The finding indicated malignancy associated changes in adhesion molecule expression to modulate cell-microenvironmental interaction.
Assessment of leukemic BM stromal microenvironment and its correlation to Wnt
LT-BMC is a powerful technique to study BM microenvironmental scenario in vitro by utilizing the ability of a specific marrow cell population to form adherent stromal cell layer (representative of microenvironmental stromal cells in vivo) under defined culture condition (Ramakrishnan et al. 2013; Chaklader and Law 2015) . Comparative LT-BMC of control and leukemic BM derived cells showed different scenario. Control marrow showed systematic generation and transformation of stromal precursors to spindle shaped stromal fibroblasts, which proliferated gradually on successive days in culture (Fig. 5a ). Leukemic marrow showed comparatively early generation and rapid transformation of stromal precursor cells to stromal fibroblasts as compared to control. The leukemic stromal cells also exhibited higher proliferation potential on successive days in culture and consequently formed homogeneous stromal fibroblast mesh-work (Fig. 5a) . The results indicated malignancy associated altered BM stromal microenvironmental scenario to support the growth and survival of highly proliferating leukemic clones. In addition, ICC was performed to study expression pattern of classical Wnt proteins in BM derived stromal cells in control and leukemic condition. Leukemic marrow derived stromal cells exhibited higher Wnt3a (Fig. 5b) and lower Wnt5a protein expression (Fig. 5c ) when compared to control. Dot blot assay showed significantly low level of Dkk1 in the leukemic stromal cell culture supernatant in comparison to control (Fig. 5d) . These results indicated the influence of malignant microenvironment behind deregulation of Wnt signaling pathway in the leukemic marrow.
Discussion
Leukemia, a hematopoietic catastrophe, develops due to sequential malignant transformation of blood forming hematopoietic stem/progenitor cells (HSPC) under the influence of the hematopoiesis supporting microenvironment (Greim et al. 2014; Anthony and Link 2014; Askmyr et al. 2011) . In the present study, we emphasized on the yet unexplored crosstalk between canonical and non-canonical Wnt signaling pathway in the HSPC compartment in leukemic condition.
The leukemic mouse model was developed by neonatal ENU induction in Swiss albino mice. The rationale behind the selection of neonatal period as the optimum time for ENU administration was twofold. It is the most crucial period when hematopoietic stem cells (HSCs) usually engage themselves to engraft in the BM to establish adult definitive hematopoiesis, after completing its journey from yolk sack to fetal liver via AGM (Aorta-Gonad-Mesonephros) and placenta during their pre-natal life. Unlike adult quiescent HSCs, the highly proliferating neonatal HSCs are comparatively more susceptible to damage by genotoxic agents like ENU as well as they exhibit minimal drug efflux efficacy. In addition, neonatal ENU injection mutates the majority of HSCs before homing to BM. Eventually these mutated clones migrate to the appropriate niches in BM, proliferates and initiates malignant hematopoiesis. This phenomena leads to irreversible leukemia development and propagation. Leukemia progression in mice was initially documented in the peripheral blood, which showed huge overshoot of the total leukocyte count and mobilization of leukemic blasts, the cardinal signs of leukemic onset. Further analysis revealed co-existence of morphologically distinct myeloblasts and lymphoblasts, which initially hinted towards development of mixed type leukemia. To further confirm we have performed cytochemistry and immunphenotyping based on highly selective lineage specific markers according to revised WHO guidelines (Vardiman et al. 2009 ) such as MPO, NSE, CD117 for myeloids, CD22, CD79a, CD10 for B-lymphoids and CD3 for T-lymphoids. Leukemic cells showed lineage specific antigen expression for both myeloids and lymphoids, which together with peripheral blood results indicated mixed type leukemia development (Law et al. 2001; Basak et al. 2010) in the adulthood after neonatal ENU challenge. We speculate that ENU, administered in the neonatal period, mutated the primitive hematopoietic population with multilineage differentiation potential, which consequently affected both the myeloid and lymphoid lineages in the later stages of life.
Next, we tried to uncover the underlying pathobiology of ENU induced leukemia by studying the Wnt signaling pathway in the primitive HSPC compartment of the above mentioned leukemic mice. Up-regulation of canonical Wnt signaling was supported by increased expression of Wnt3a protein and Fzd7 receptor in the leukemic condition, which led to stabilization and eventual increase of total cellular β-catenin level as confirmed by flow cytometry. Signaling up-regulation was also supported by the declined expression of canonical Wnt antagonist Dkk1. Wnt signaling controls multiple cellular mechanisms in a context dependent manner and the present study identified that spike in canonical Wnt facilitated the excessive proliferation of leukemic clones via up-regulation of CyclinD1, the direct target gene of β-catenin, which is required for cell cycle entry and subsequent cell proliferation (Shtutman et al. 1999; Stacey 2003) . A previous report by our group also has shown that leukemic cells are highly proliferating in nature (Chatterjee et al. 2009d) . After unveiling the canonical Wnt scenario in the leukemic BM HSPC compartment, we focused on the noncanonical Wnt pathways such as Wnt5a/Ca 2+ and Wnt5a/ ROR2. Unlike Wnt3a, Wnt5a expression in the leukemic HSPC compartment was significantly low, which was preferable for leukemic cells but detrimental for patients or the experimental subjects as Wnt5a acts as a tumor suppressor in hematological malignancies. However the exact mechanism of Wnt5a mediated anti-tumor activity is elusive. 
Wnt3a
Cell proliferation Fig. 6 Schematic representation of deregulated Wnt signaling pathways in the BM of ENU induced experimental leukemic mice suppresses CREB associated gene transcription such as CyclinD1 which contains a c-AMP response element in its promoter (Wu and McMurray 2001; Guo et al. 2011 ) and in turn inhibits proliferation. In our leukemic model, CyclinD1 elevation as a result of activated canonical Wnt3a/β-catenin signaling also partly supported by down-regulation of Wnt5a/Ca 2+ / CaMKII pathway. Moreover, Wnt5a induces ROR2 (an orphan receptor tyrosine kinase) expression and kinase activity and Wnt5a/ROR2 signaling antagonizes canonical Wnt signaling by inhibiting β-catenin/TCF (T-cell factor, a co-activator of β-catenin) transcription activation potential and eventually CyclinD1 expression (Yuan et al. 2011; Mikels et al. 2009 ). ENU induced leukemic cells showed decreased ROR2 expression along with Wnt5a. Thus, down-regulated Wnt5a/ROR2 signaling further facilitated proliferation of leukemic clones via CyclinD1 expression and unhindered canonical Wnt/β-catenin signaling. Next, we tried to suppress, in part, up-regulated Wnt3a/β-catenin pathway by anti-Wnt3a antibody in the in vitro hematopoietic clonogenicity assay to see whether leukemic primitive hematopoietic compartment was responsive to Wnt3a protein for abnormal proliferation. We observed that the numbers of primitive leukemic hematopoietic CFU-GEMM and BFU-E colonies were reduced due to supplementation of anti-Wnt3a antibody, probably due to lack of functional Wnt3a protein availability to bind to the Fzd receptor of the responding cells.
We also identified overexpressed N-Cadherin (CD325), a cell adhesion molecule, in the leukemic HSPC compartment, which is required for adhesion and retention of primitive leukemic cells in the BM microenvironment to get a shelter and in turn provides protection from chemotherapeutic challenge (Zhang et al. 2013 ). Thus, up-regulation of N-cadherin after ENU administration in the leukemic condition was probably to get more microenvironmental support through the homophilic interaction with NCadherin expressing stromal cells. Moreover, N-Cadherin positive cells produce increased numbers of hematopoietic colonies with cytokine stimulation due to higher proliferative capacity and few reports claimed that leukemic stem cell activity is present in the N-Cadherin positive population which engrafts well in the immunodeficient mice upon transplantation (Pawar et al. 2015; Zhi et al. 2016; Qiu et al. 2014) .
In addition to alteration of Wnt signaling in the leukemic HSPC compartment, malignant stromal microenvironment also adversely influenced paracrine Wnt protein expression pattern. LT-BMC showed early generation of stromal cells from the leukemic BM (as compared to control), which proliferated rapidly on successive days and formed homogenous stromal network. The result indicated malignancy associated alteration in BM stromal microenvironmental scenario to support growth and survival of highly proliferating leukemic clones. Brenner et al. 2017 also has shown that patient derived leukemic cells co-cultered with human MSCs exhibit higher proliferation capacity and decreased cell death rate. Although neoplastic cells are well equipped with intrinsic growth and survival mechanisms, the interaction of leukemic cells with microenvironment is indispensable for leukemia development and propagation. Leukemic microenvironment provides a favourable ambience for malignant cell growth by releasing several soluble factors in addition to direct physical contact via modulation of membrane bound receptors and adhesion molecules. Studies have shown that stroma derived Wnt can modulate the activity of hematopoietic cells (Fleming et al. 2008; Schaniel et al. 2011) . In our study, we observed the involvement of stroma derived Wnt behind alteration of Wnt signaling pathway in the ENU induced leukemic hematopoietic cells. Leukemic stromal cells showed differential expression of Wnts such as increased canonical Wnt ligand -Wnt3a and decreased non-canonical Wnt ligand -Wnt5a along with reduced Wnt antagonist Dkk1, which further supported up-regulation of canonical Wnt3a signaling and down-regulation of noncanonical Wnt5a signaling in the leukemic hematopoietic cells.
Taken together, our study demonstrated that uncoordinated interplay between canonical and non-canonical Wnt signaling pathways in the leukemic HSPC compartment was supported by deregulation of leukemic cell intrinsic mechanisms as well as alteration of BM stromal microenvironment (Fig. 6) , which contributed to the leukemic disease progression in the ENU induced experimental leukemic mice. The present investigation revealed the mechanistic interplay between different branches of developmentally significant Wnt signaling pathway in hematopoietic malignant condition that can be employed in future to understand disease mechanisms involved in other malignant conditions as well as in developmental disorders.
